Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT00279760. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized, double-blind, placebo controlled, parallel and multiple dose study provided safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and BMS-224818 in subjects with RA
Study identification
- NCT ID
- NCT00279760
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Feb 28, 2002
- Completion
- Not listed
- Last update posted
- Sep 15, 2016
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Birmingham | Alabama | — | — |
| Local Institution | Huntsville | Alabama | — | — |
| Local Institution | Phoenix | Arizona | — | — |
| Local Institution | Tucson | Arizona | — | — |
| Local Institution | Los Angeles | California | — | — |
| Local Institution | San Diego | California | — | — |
| Local Institution | Miami | Florida | — | — |
| Local Institution | Chicago | Illinois | — | — |
| Local Institution | Boston | Massachusetts | — | — |
| Local Institution | Duluth | Minnesota | — | — |
| Local Institution | New Brunswick | New Jersey | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Chapel Hill | North Carolina | — | — |
| Local Institution | Cincinnati | Ohio | — | — |
| Local Institution | Cleveland | Ohio | — | — |
| Local Institution | Portland | Oregon | — | — |
| Local Institution | Nashville | Tennessee | — | — |
| Local Institution | Dallas | Texas | — | — |
| Local Institution | Salt Lake City | Utah | — | — |
| Local Institution | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00279760, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2016 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00279760 live on ClinicalTrials.gov.